Epstein-Barr Viral Infections - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Epstein-Barr Viral Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Epstein-Barr Viral Infections - Pipeline Review, H2 2016', provides an overview of the Epstein-Barr Viral Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Epstein-Barr Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epstein-Barr Viral Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epstein-Barr Viral Infections
- The report reviews pipeline therapeutics for Epstein-Barr Viral Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Epstein-Barr Viral Infections therapeutics and enlists all their major and minor projects
- The report assesses Epstein-Barr Viral Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Epstein-Barr Viral Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Epstein-Barr Viral Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Epstein-Barr Viral Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Epstein-Barr Viral Infections Overview 9
Therapeutics Development 10
Pipeline Products for Epstein-Barr Viral Infections - Overview 10
Pipeline Products for Epstein-Barr Viral Infections - Comparative Analysis 11
Epstein-Barr Viral Infections - Therapeutics under Development by Companies 12
Epstein-Barr Viral Infections - Therapeutics under Investigation by Universities/Institutes 13
Epstein-Barr Viral Infections - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Epstein-Barr Viral Infections - Products under Development by Companies 17
Epstein-Barr Viral Infections - Products under Investigation by Universities/Institutes 18
Epstein-Barr Viral Infections - Companies Involved in Therapeutics Development 19
Arno Therapeutics, Inc. 19
Cell Medica Limited 20
Epiphany Biosciences, Inc. 21
Genocea Biosciences, Inc. 22
Humabs BioMed SA 23
Molplex Ltd. 24
Omeros Corporation 25
Savoy Pharmaceuticals, Inc. 26
Theravectys SA 27
Vironika, LLC 28
ViroStatics srl 29
Epstein-Barr Viral Infections - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
AR-12 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Cellular Immunotherapy for EBV Associated PTLD - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Cellular Immunotherapy for Infectious Disease - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Cellular Immunotherapy for Infectious Diseases - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Cellular Immunotherapy for Systemic Lupus Erythematosus and Epstein-Barr Viral Infections - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Cellular Immunotherapy for Viral Infections - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Cellular Immunotherapy to Target Calcineurin A for EBV associated post transplant B cell lymphoma - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CMD-003 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Epstein-Barr virus (virus like particle) vaccine - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Epstein-Barr virus vaccine - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Monoclonal Antibody for Epstein-Barr Viral Infection - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
MVA vaccine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecule for Infectious Mononucleosis - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecules to Inhibit EBNA1 for Epstein-Barr Viral Infections - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Vaccine for Epstein-Barr Virus and Oncology - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
valomaciclovir stearate - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Viroprev - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Epstein-Barr Viral Infections - Dormant Projects 68
Epstein-Barr Viral Infections - Product Development Milestones 69
Featured News & Press Releases 69
Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Number of Products under Development for Epstein-Barr Viral Infections, H2 2016 10
Number of Products under Development for Epstein-Barr Viral Infections - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Epstein-Barr Viral Infections - Pipeline by Arno Therapeutics, Inc., H2 2016 19
Epstein-Barr Viral Infections - Pipeline by Cell Medica Limited, H2 2016 20
Epstein-Barr Viral Infections - Pipeline by Epiphany Biosciences, Inc., H2 2016 21
Epstein-Barr Viral Infections - Pipeline by Genocea Biosciences, Inc., H2 2016 22
Epstein-Barr Viral Infections - Pipeline by Humabs BioMed SA, H2 2016 23
Epstein-Barr Viral Infections - Pipeline by Molplex Ltd., H2 2016 24
Epstein-Barr Viral Infections - Pipeline by Omeros Corporation, H2 2016 25
Epstein-Barr Viral Infections - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 26
Epstein-Barr Viral Infections - Pipeline by Theravectys SA, H2 2016 27
Epstein-Barr Viral Infections - Pipeline by Vironika, LLC, H2 2016 28
Epstein-Barr Viral Infections - Pipeline by ViroStatics srl, H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Stage and Target, H2 2016 32
Number of Products by Stage and Mechanism of Action, H2 2016 34
Number of Products by Stage and Route of Administration, H2 2016 36
Number of Products by Stage and Molecule Type, H2 2016 38
Epstein-Barr Viral Infections - Dormant Projects, H2 2016 68